[Cipaglucosidase alfa (Pompe disease) – Benefit assessment according to § 35a Social Code Book (SGB) V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005378
German
Original Title:
Cipaglucosidase alfa (Morbus Pompe)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-79.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-79_cipaglucosidase-alfa_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Glycogen Storage Disease Type II
- Enzyme Inhibitors
- Glycoside Hydrolase Inhibitors
- 1-Deoxynojirimycin
- Enzyme Replacement Therapy
Keywords
- Cipaglucosidase alfa
- Miglustat
- Glycogen Storage Disease Type II
- Benefit Assessment
- NCT03729362
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.